Abstract:
Currently the increased focus is being given to reforming osteoporosis regimens. Optimizing the evaluation of
pharmacological intervention occurs once a medicine has been approved. There is literature available on the use of
alendronate in bone loss. The current study focuses on the efficacy assessment of alendronate on proximal femur bone
density loss. Current work was carried out to analyze the data of the BMD. The study comprised of females who had
received at least six months of Alendronate (70mg/week) for proximal femur osteoporosis. SPSS version-22 was used
for analysis and a comparative change was regarded therapeutically significant. The reliability of the research was
ensured by reporting cover-up and withdrawals. Among all the study participants who received Alendronate therapy the
median height of females in centimeters (cms) was 155 (IQR =16) and the median weight was 55.5 Kilograms (Kgs)
(IQR =15). The mean age of the population was 50.59±14.714. The study found the median T-score before therapy was
-2.9 (IQR=0.7) and the median T-score after therapy was -2.51(IQR=1). The estimated difference of mean rank was
statistically significant for pre- and post-therapy T-score (p=0.008). Hence, the results of this study indicate an
improvement in BMD as a result of therapy. Alendronate at 70 mg per week is effective in reducing hip osteoporosis
